Check patentability & draft patents in minutes with Patsnap Eureka AI!

Application of cinnamaldehyde in preparation of medicine for treating ovarian epithelial cancer and medicine preparation of cinnamaldehyde

A technology of ovarian epithelial cancer and pharmaceutical preparations, applied in the field of drugs for the treatment of ovarian epithelial cancer and its pharmaceutical preparations, can solve the problems of drug resistance, many adverse reactions, and high prices

Pending Publication Date: 2021-12-17
XUZHOU MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the clinically used drugs for the treatment of epithelial ovarian cancer mainly include platinum drugs, paclitaxel drugs, bevacizumab and polyadenosine diphosphate-ribose polymerase (polyADPribosepolymerase, PARP) inhibitors and other molecular targeted drugs, but there are still Many adverse reactions, drug resistance, broad-spectrum anti-cancer, expensive and other disadvantages, and the current overall survival rate of ovarian epithelial cancer in the world has not significantly improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cinnamaldehyde in preparation of medicine for treating ovarian epithelial cancer and medicine preparation of cinnamaldehyde
  • Application of cinnamaldehyde in preparation of medicine for treating ovarian epithelial cancer and medicine preparation of cinnamaldehyde
  • Application of cinnamaldehyde in preparation of medicine for treating ovarian epithelial cancer and medicine preparation of cinnamaldehyde

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1: Detection of EMT activity inhibited by cinnamaldehyde

[0044] 1. In the western-blot detection method, A2780 and SKOV3 were divided into 4 groups respectively, and the experimental groups were as follows:

[0045] Experimental group 1: 0ug / ml cinnamaldehyde

[0046] Experimental group 2: 5ug / ml cinnamaldehyde

[0047] Experimental group 3: 10ug / ml cinnamaldehyde

[0048] Experimental group 4: 20ug / ml cinnamaldehyde

[0049] In the immunofluorescence detection method, A2780 and SKOV3 were divided into 3 groups, and the experimental groups were as follows:

[0050] Experimental group 1: 0ug / ml cinnamaldehyde

[0051] Experimental group 2: 10ug / ml cinnamaldehyde

[0052] Experimental group 3: 20ug / ml cinnamaldehyde

[0053] 2. Cell Processing

[0054] After A2780 and SKOV3 cells adhered to the wall, when the density was about 80%, the corresponding concentration of cinnamaldehyde was added to each group for 48 hours.

[0055] 3. Use Western-blot detecti...

Embodiment 2

[0093] Example 2: Cinnamaldehyde inhibits the proliferation and invasion of ovarian epithelial cancer cells

[0094] 1. A2780, SKOV3 and IOSE80 are divided into 6 groups respectively, and the experimental groups are as follows:

[0095] Experimental group 1: 0ug / ml cinnamaldehyde

[0096] Experimental group 2: 0.5ug / ml cinnamaldehyde

[0097] Experimental group 3: 1ug / ml cinnamaldehyde

[0098] Experimental group 4: 5ug / ml cinnamaldehyde

[0099] Experimental group 5: 10ug / ml cinnamaldehyde

[0100] Experimental group 6: 20ug / ml cinnamaldehyde

[0101] 2. CCK8 experiment, the steps are as follows:

[0102] (1) Plating and dosing: select cells in the logarithmic growth phase, digest and count, and adjust the cell concentration to 4×10 4 / ml, inoculated in a 96-well plate, 100 μL per well, and an appropriate amount of PBS was added around the 96-well plate to prevent water evaporation. After the cells adhered to the wall, starve overnight with serum-free medium, add the c...

Embodiment 3

[0116] Example 3: Cinnamaldehyde can promote the apoptosis of ovarian epithelial cancer cells

[0117] 1. A2780 and SKOV3 are divided into 3 groups respectively, and the experimental groups are as follows:

[0118] Experimental group 1: 0ug / ml cinnamaldehyde

[0119] Experimental group 2: 5ug / ml cinnamaldehyde

[0120] Experimental group 3: 20ug / ml cinnamaldehyde

[0121] 2. Flow cytometry detection, the steps are as follows:

[0122] (1) Cells were seeded in a six-well plate with a density of about 80%. After the cells adhered to the wall, corresponding doses of cinnamaldehyde were added according to different groups and treated for 48 hours;

[0123] (2) Digest the cells with EDTA-free trypsin (note that the trypsin digestion time should not be too long), add complete medium to terminate the reaction, transfer the cells into a centrifuge tube, centrifuge at 2000rpm for 5min, discard the supernatant, and add an appropriate amount of complete medium to adjust the cells The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of cinnamaldehyde in preparation of a medicine for treating ovarian epithelial cancer and a medicine preparation of the cinnamaldehyde, and belongs to the field of biological medicine. Experimental results show that cinnamaldehyde can inhibit proliferation, migration and invasion of ovarian epithelial cancer cells by reversing an EMT process, so that growth of the ovarian epithelial cancer cells is inhibited. Cinnamaldehyde has relatively small toxicity to normal ovarian epithelial cells, which indicates that cinnamaldehyde has relatively small damage to normal human cells; cinnamaldehyde inhibits proliferation, migration and invasion of ovarian epithelial cancer cells by reversing an EMT process instead of directly killing the ovarian epithelial cancer cells, so that drug resistance is not easy to generate; and cinnamaldehyde has an obvious inhibition effect on growth of transplanted ovarian epithelial cancer in nude mice, and has a good application prospect in research and development of novel anti-ovarian epithelial cancer drugs. The application field of cinnamaldehyde is widened, an experimental basis is provided for clinical application of cinnamaldehyde in preparation of the medicine for treating ovarian epithelial cancer, and the cinnamaldehyde has a good application prospect and a huge potential value.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of cinnamaldehyde in the preparation of medicines for treating ovarian epithelial cancer and its pharmaceutical preparations. Background technique [0002] Ovarian cancer is one of the deadliest gynecological tumors. About 239,000 people worldwide are diagnosed with ovarian cancer each year, and 152,000 people die from the disease and its complications. Epithelial ovarian cancer is the main type of ovarian cancer. Due to the lack of effective early screening methods, most ovarian cancer patients are already at an advanced stage when they are diagnosed. Currently, the first-line treatment for ovarian epithelial cancer includes surgery and adjuvant chemotherapy. The five-year survival rate of patients diagnosed with stage III or IV epithelial ovarian cancer is less than 25%, although most patients respond to treatment at the initial stage of treatment. Drug sen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/11A61K36/54A61P35/00A61K135/00
CPCA61K31/11A61K36/54A61P35/00
Inventor 蓝婷王悦王忠诚穆春艳
Owner XUZHOU MEDICAL UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com